Literature DB >> 21835798

Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Chavdar Krachmarov1, Zhong Lai, William J Honnen, Aidy Salomon, Miroslaw K Gorny, Susan Zolla-Pazner, James Robinson, Abraham Pinter.   

Abstract

A series of potently neutralizing monoclonal antibodies (MAbs) that target quaternary epitopes on the native Env trimer have recently been described. A common feature shared by these antibodies is the critical involvement of sites in both the V2 and V3 variable domains in antibody recognition. In this study the gp120 variable-region determinants were mapped for eight rhesus macaque monoclonal antibodies (RhMAbs) possessing potently neutralizing activity specific for a quaternary target in SF162 Env and compared to those originally identified for human MAb 2909. These studies showed that determinants for the epitopes defined by the RhMAbs differed in both the V2 (positions 160, 167, and 169) and V3 (positions 313 and 315) regions from 2909, and in a number of cases, from each other. Attempts to reconstitute expression of these epitopes on the cell surface by cotransfecting Envs containing either the V2 or the V3 determinant of the epitope were not successful, suggesting that these epitopes were expressed on individual protomers in a trimer-dependent manner. Several of the V2 positions found to be critical for expression of these quaternary epitopes also significantly affected exposure and neutralization sensitivity of targets in the V3 and CD4-binding domains. These results demonstrated a considerable diversity in the fine structure of this class of epitopes and further suggested a potentially important relationship between the expression of such quaternary epitopes and V1/V2-mediated masking of immunodominant epitopes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835798      PMCID: PMC3187505          DOI: 10.1128/JVI.00365-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain.

Authors:  Z Wu; S C Kayman; W Honnen; K Revesz; H Chen; S Vijh-Warrier; S A Tilley; J McKeating; C Shotton; A Pinter
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

3.  Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.

Authors:  K Schønning; B Jansson; S Olofsson; J E Hansen
Journal:  J Gen Virol       Date:  1996-04       Impact factor: 3.891

4.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120.

Authors:  S A Tilley; W J Honnen; M E Racho; T C Chou; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

6.  An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

Authors:  N K Back; L Smit; J J De Jong; W Keulen; M Schutten; J Goudsmit; M Tersmette
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

7.  Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.

Authors:  M K Gorny; A J Conley; S Karwowska; A Buchbinder; J Y Xu; E A Emini; S Koenig; S Zolla-Pazner
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

9.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

Authors:  M Purtscher; A Trkola; G Gruber; A Buchacher; R Predl; F Steindl; C Tauer; R Berger; N Barrett; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

10.  Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.

Authors:  K Schønning; B Jansson; S Olofsson; J O Nielsen; J S Hansen
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

View more
  14 in total

1.  Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Authors:  Axel Mann; Nikolas Friedrich; Anders Krarup; Jacqueline Weber; Emanuel Stiegeler; Birgit Dreier; Pavel Pugach; Melissa Robbiani; Tina Riedel; Kerstin Moehle; John A Robinson; Peter Rusert; Andreas Plückthun; Alexandra Trkola
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

2.  Sequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein.

Authors:  Evgeny Shmelkov; Arsen Grigoryan; Chavdar Krachmarov; Ruben Abagyan; Timothy Cardozo
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-14       Impact factor: 2.205

3.  Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.

Authors:  Zakiya M Qualls; Alok Choudhary; William Honnen; Raja Prattipati; James E Robinson; Abraham Pinter
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

4.  Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Authors:  Aidy Salomon; Chavdar Krachmarov; Zhong Lai; William Honnen; Barry S Zingman; Julie Sarlo; Miroslaw K Gorny; Susan Zolla-Pazner; James E Robinson; Abraham Pinter
Journal:  Virology       Date:  2013-11-12       Impact factor: 3.616

Review 5.  Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.

Authors:  F Benjelloun; P Lawrence; B Verrier; C Genin; S Paul
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

6.  Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.

Authors:  Javier F Morales; Bin Yu; Gerardo Perez; Kathryn A Mesa; David L Alexander; Phillip W Berman
Journal:  Mol Immunol       Date:  2016-07-21       Impact factor: 4.407

7.  Rapid, quantitative mapping of anti-HIV type 1 envelope serum antibody specificities.

Authors:  Rebecca L R Powell; Ross W B Lindsay; Aaron Wilson; Alexei Carpov; Svetlana Rabinovich; Simon Hoffenberg; Michael J Caulfield
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

8.  Conference report: "Functional Glycomics in HIV Type 1 Vaccine Design" workshop report, Bethesda, Maryland, April 30-May 1, 2012.

Authors:  Angela Malaspina; Brenda S Collins; Anne Dell; Galit Alter; Thandi M Onami
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-19       Impact factor: 2.205

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies.

Authors:  Laura E McCoy; Marit J van Gils; Gabriel Ozorowski; Terrence Messmer; Bryan Briney; James E Voss; Daniel W Kulp; Matthew S Macauley; Devin Sok; Matthias Pauthner; Sergey Menis; Christopher A Cottrell; Jonathan L Torres; Jessica Hsueh; William R Schief; Ian A Wilson; Andrew B Ward; Rogier W Sanders; Dennis R Burton
Journal:  Cell Rep       Date:  2016-08-18       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.